The proposed mechanism of action for OCREVUS

Directed Against CD20-Expressing B Cells
OCREVUS® (ocrelizumab) mechanism of action

OCREVUS is a recombinant humanized monoclonal antibody directed against CD20-expressing B cells. Lymphoid stem cells and plasma cells do not express CD20 and therefore are not directly targeted by OCREVUS. 1

The precise mechanisms through which OCREVUS exerts its therapeutic clinical effects in RMS and PPMS are not fully elucidated but are presumed to involve immunomodulation through selective binding to CD20-expressing B cells. Following cell surface binding to B lymphocytes, OCREVUS results in antibody-dependent cellular cytolysis and complement-mediated lysis.

Want to learn more about OCREVUS?

Sign up to speak with an OCREVUS clinical specialist.

OCREVUS clinical pharmacology

Learn more about the pharmacodynamics and pharmacokinetics of OCREVUS in the full Prescribing Information.